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Abstract
Gut microorganisms are vital for many aspects of human health, and the commensal
bacterium Akkermansia muciniphila has repeatedly been identified as a key compo-
nent of intestinal microbiota. Reductions in A. muciniphila abundance are associated
with increased prevalence of metabolic disorders such as obesity and type 2 diabetes.
It was recently discovered that administration of A. muciniphila has beneficial effects
and that these are not diminished, but rather enhanced after pasteurization. Pasteur-
ized A. muciniphila is proposed for use as a food ingredient, and was therefore sub-
jected to a nonclinical safety assessment, comprising genotoxicity assays (bacterial
reverse mutation and in vitro mammalian cell micronucleus tests) and a 90-day toxic-
ity study. For the latter, Han Wistar rats were administered with the vehicle or pas-
teurized A. muciniphila at doses of 75, 375 or 1500 mg/kg body weight/day
(equivalent to 4.8 × 109, 2.4 × 1010, or 9.6 × 1010 A. muciniphila cells/kg body
weight/day) by oral gavage for 90 consecutive days. The study assessed potential
effects on clinical observations (including detailed arena observations and a modified
Irwin test), body weight, food and water consumption, clinical pathology, organ
weights, and macroscopic and microscopic pathology. The results of both in vitro
genotoxicity studies were negative. No test item-related adverse effects were
observed in the 90-day study; therefore, 1500 mg/kg body weight/day (the highest
dose tested, equivalent to 9.6 × 1010 A. muciniphila cells/kg body weight/day) was
established as the no-observed-adverse-effect-level. These results support that pas-
teurized A. muciniphila is safe for use as a food ingredient.
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1 | INTRODUCTION
Akkermansia muciniphila is an elliptical-shaped human gut commensal
bacterium that is nonmotile and does not form spores. It was isolated
from the human gastrointestinal tract for the first time by Derrien and
colleagues in 2004 (Derrien, Vaughan, Plugge, & de Vos, 2004). The
relative abundance of A. muciniphila found in fecal samples derived
from healthy humans ranges from 0.5% to 5% (Collado, Derrien,
Isolauri, de Vos, & Salminen, 2007; Derrien, Collado, Ben-Amor,
Salminen, & de Vos, 2008). Primarily considered to reside in the large
intestine, data suggest that the small intestine can also be colonized
by several A. muciniphila cells (Geerlings, Kostopoulos, de Vos, &
Belzer, 2018). A. muciniphila is present in the human gut from infancy
(as young as 1 month old), and its abundance increases significantly
during growth into adulthood. A. muciniphila cells have been detected
in human breast milk (Collado, Laitinen, Salminen, & Isolauri, 2012),
thus demonstrating A. muciniphila consumption from birth through
infant consumption of breast milk. The capacity of A. muciniphila to
use human milk oligosaccharides as a sole energy, carbon and nitrogen
source, could explain its presence in breast milk and the breast tissue
of lactating woman (Collado et al., 2012; Ottman, 2017). Human milk
may act as a carrier for A. muciniphila in the transfer from mother to
infant, explaining the presence of A. muciniphila in the infant intestine
already early in life. Furthermore, another characteristic of
A. muciniphila can also facilitate this transfer from mother to infant.
Indeed, A. muciniphila has an active acid resistance system
(Ottman, 2017). This system, together with the mild acidic conditions
in the infant stomach during early life, could help A. muciniphila to
reach and colonize the intestine in early life.
Recently, combined analysis of large global datasets (3984
subjects) revealed that the genus Akkermansia was present in 77.73%
of the total assessed cohorts globally and in 81.81% of cohorts
targeting Western populations (Falony et al., 2016). In a study com-
prising 249 subjects across various age groups, A. muciniphila was
detected in eight of 50 fecal samples of 1-month-old infants (16%), in
36 of 50 children aged 6 months (72%), in 45 of 50 children at
12 months of age (90%), and in 96 to 100% of samples from adults
and the elderly (Collado et al., 2007).
Inspired by the numerous observations that the relative levels of
A. muciniphila decreased during obesity andmetabolic disorders in mice
and humans (for review: Cani & de Vos, 2017; Derrien, Belzer, & de
Vos, 2017; Xu et al., 2020), further studies were conducted to investi-
gate the causal link betweenA. muciniphila and improvements inmetab-
olism. It was found that the administration of live A. muciniphila partly
protected against diet-induced obesity, diabetes and gut barrier dys-
function in mice (Everard et al., 2013). Indeed, the oral administration of
live A. muciniphilawas able to counteract the bodyweight gain, fat mass
gain and glucose intolerance induced by high-fat feeding in murine
models. In addition, daily supplementation with live A. muciniphila was
associated with a decrease of plasmatic level of lipopolysaccharides and
an increase of mucus thickness and expression of antimicrobial peptide
mRNA, which showed an overall improvement of the gut barrier
function; a function usually altered in diet-induced obesitymicemodels.
Another key finding of this study was that the protective effects of
A. muciniphila disappeared when the bacterium was heat-killed by
autoclaving (15 minutes at 121C), which is a heating procedure that
destroyed all constituents of the bacteria (Everard et al., 2013). As
A. muciniphila is a gram-negative bacterium, and hence a nonspore for-
mer, research was conducted to elucidate whether the removal of the
protective effects of A. muciniphila observed after autoclaving would
also be seen after pasteurization (30 minutes at 70C), which is a milder
heat-inactivation method compared with autoclaving. In a study
assessing the effects of pasteurized A. muciniphila on diet-induced
metabolic disorders in mice, not only was it found that pasteurization
did not diminish the beneficial effects, but it unexpectedly enhanced
the beneficial impact of A. muciniphila (Plovier et al., 2005). Since this
discovery, the beneficial effects of pasteurized A. muciniphila in the
prevention of metabolic disorders associated with obesity have been
confirmed in mice (Depommier et al., 2020) and in humans
(Depommier et al., 2019). Depommier et al. (2020) confirmed that
daily administration of pasteurized A. muciniphila alleviates diet-
induced obesity in mice. Furthermore, Depommier et al. (2020)
explored the mechanism of action underlaying the observed beneficial
effects more thoroughly and found that administration of pasteurized
A. muciniphila is able to impact the whole-body energy metabolism by
increasing energy expenditure, spontaneous physical activity and fecal
energy excretion in a diet-induced obesity mice model. A randomized,
double-blind, placebo-controlled proof-of-concept study in over-
weight/obese insulin-resistant human volunteers showed that the
daily supplementation with pasteurized A. muciniphila at a dose of
1 × 1010 cells per day for 12 weeks improved several metabolic
parameters such as insulin sensitivity, insulinemia, plasma total choles-
terol, as well as relevant blood markers for liver dysfunction and
inflammation independently of any caloric restriction or modification
of the physical activity (Depommier et al., 2019). Recently, the benefi-
cial effects of pasteurized A. muciniphila were also demonstrated in
the context of colitis and colitis-associated colorectal cancer (Wang
et al., 2019). Oral administration of pasteurized A. muciniphila from
2 weeks before dextran sulfate sodium treatment and until death was
associated with a reduction of disease severity (reduction of colon
shortening and splenomegaly; attenuation of histological injuries in
the colon). Furthermore, in a model of colitis-associated colorectal
cancer, the oral administration of pasteurized A. muciniphila was able
to delay the tumor formation and decrease the tumor numbers and
size. These results suggest that this decreased tumorigenesis could
be mediated by an attenuation of DNA damage, cell apoptosis and
abnormal proliferation.
Pasteurized A. muciniphila has now been developed for use as a
food ingredient. As A. muciniphila is a highly prevalent intestinal
microbe colonizing virtually all healthy subjects studied and is detected
in breast milk, it can be argued that it has some history of consumption
(Gómez-Gallego, Pohl, Salminen, De Vos, & Kneifel, 2016). However,
pasteurized A. muciniphila (produced by fermentation, pasteurization
and freeze-drying) is considered a novel food and therefore
requires a thorough safety assessment before being approved as a
food ingredient.
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Although detected in breastmilk,A.muciniphila is not absorbed into
the systemic circulation to any significant extent, which is similar to
other nonabsorbable compounds found in breast milk, such as human
milk oligosaccharides, which are considered as nondigestible carbohy-
drates (EFSA, 2016). A. muciniphila is almost exclusively excreted in
feces following oral administration. Preclinical and clinical studies have
shown that A. muciniphila supplementation does not induce major
changes in the overall gut microbiome (Depommier et al., 2019; Everard
et al., 2013). The detection of A. muciniphila in fecal samples in these
preclinical and clinical studies demonstrates that it is excreted in feces.
Pasteurization is not expected to change the profile of
A. muciniphila; thus, pasteurized A. muciniphila is also expected to be
nonabsorbable. Following the US Food and Drug Administration (FDA)
and European Food Safety Authority (EFSA) guidances on toxicity test-
ing required for safety assessment of a new nonabsorbable food ingre-
dient (EFSA, 2012; US FDA Redbook, 2014), pasteurized A. muciniphila
was subjected to nonclinical studies assessing the potential for gen-
otoxicity (bacterial reverse mutation and in vitro micronucleus testa on
mammalian cells) and subchronic toxicity (90-day oral toxicity study in
rats). The objective of this research article is to describe the methodol-
ogy and results for these nonclinical studies conducted with pasteur-
ized A. muciniphila, as part of a comprehensive assessment to
demonstrate its safety for use as a food ingredient.
2 | MATERIALS AND METHODS
2.1 | Regulatory guidelines and quality assurance
The studies were performed at two of Citoxlab's Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC)-
accredited facilities (genotoxicity studies conducted at Citoxlab
France and 90-day study conducted at Citoxlab Denmark) and
inspected by Quality Assurance Units in compliance with the Organi-
zation for Economic Co-operation and Development (OECD)
Principles of Good Laboratory Practice (OECD, 1998). All studies were
conducted following OECD guidelines: the 90-day oral gavage toxicity
study was conducted using test methods described in OECD Test
Guideline No. 408 (OECD, 2018), the bacterial reverse mutation test
was conducted according to OECD Test Guideline No. 471
(OECD, 1997), and the in vitro micronucleus test on mammalian
cells was conducted according to OECD Test Guideline
No. 487 (OECD, 2016). The housing of the animals was in accordance
with EU Directive 2010/63/EU of September 22, 2010 on the protec-
tion of animals used for scientific purposes (European Union, 2010).
2.2 | Test materials
Pasteurized A. muciniphila (strain MucT [ATCC BAA-835]) was supplied
by A-Mansia Biotech SA as an off-white to beige homogeneous powder
and contained at least 2.5 × 1010 A. muciniphila cells per gram of pow-
der; viable cells represent ≤0.0001% of this total cell count. The vehicle
for the 90-day study (sterile phosphate-buffered saline) was supplied
by Sigma-Aldrich. Water for injection (CDM Lavoisier) served as the
vehicle and negative control for both genotoxicity studies. Positive con-
trols used in the bacterial reverse mutation test were supplied by
Sigma-Aldrich (sodium azide, 9-aminoacridine, 2-anthramine, benzo[a]
pyrene and 2-nitrofluorene) and by Acros Organics BVBA (mitomycin
C) and all except for mitomycin C (dissolved in water) were dissolved in
dimethyl sulfoxide (Merck KGaA) before use. The five strains of Salmo-
nella typhimurium TA1535, TA1537, TA98, TA100 and TA102 used in
the bacterial reverse mutation test were supplied by Moltox or culture
collections (Public Health England). Positive controls used in the in vitro
micronucleus test on mammalian cells were supplied by Sigma-Aldrich
(colchicine and cyclophosphamide) and by Acros Organics BVBA (mito-
mycin C), and dissolved in water before use. Liver homogenate used to
replicate metabolic activation (S9 mix) was supplied by Moltox and
obtained from the liver of rats previously administered with 500 mg/kg
Aroclor 1254 by intraperitoneal injection.
2.3 | Genotoxicity
2.3.1 | Bacterial reverse mutation test (Ames test)
The bacterial reverse mutation test was conducted using the plate
incorporation and preincubation methods, as has been previously
described (Ames, McCann, & Yamasaki, 1975; Maron & Ames, 1983).
S. typhimurium strains TA98, TA100, TA102, TA1535 and TA1537
were exposed to pasteurized A. muciniphila at concentrations of up to
the OECD Test Guideline No. 471 (OECD, 1997) maximum rec-
ommended concentration of 5000 μg/plate, in the absence or pres-
ence of external metabolic activation (S9 mix). The only exception
was for the TA98 strain in the presence of the S9 mix, where the high
dose was limited by cytotoxicity (highest tested concentration of
555.6 μg/plate using the direct plate incorporation method and
1666.7 μg/plate following the preincubation method).
For the direct plate incorporation method, 0.1 mL suspensions of
pasteurized A. muciniphila were mixed with 0.5 mL of S9 mix or
pH 7.4 phosphate buffer (depending on whether metabolic activation
was required), 0.1 mL of a suspension of each bacterial strain and
2 mL of overlay agar containing Agar (BD Biosciences), NaCl (CDM
Lavoisier), D(+) Biotine (Sigma-Aldrich) and L-Histidine (Sigma-Aldrich).
After rapid homogenization (a few minutes by vortex), the mixture
was overlaid on to a Petri dish containing minimum medium (Trinova
Biochem GmbH). The same quantities of test item suspensions
(0.1 mL), S9 mix (0.5 mL) and bacterial suspensions (0.1 mL) were used
for the preincubation method, but the mixture was then preincubated
for 60 minutes at 37C (under shaking) before overlay agar was added
and the mixture was poured on to the surface of a minimum agar
plate. For both methods, after 48-72 hours of incubation at 37C, the
number of revertants per plate were scored for each strain and for
each experimental point using an automatic counter (Sorcerer Auto-
matic Colony Counter [Perceptive Instruments Ltd.] for the scoring of
colonies and Ames Study Manager [Perceptive Instruments Ltd.] for
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the data management). Manual counting was used when required.
Thinning of the bacterial lawn and the presence of precipitate were
assessed visually with the naked eye.
A positive result for mutagenicity was defined as a reproducible
two- or three-fold increase in the number of revertant colonies, com-
pared with vehicle controls, and/or a reproducible dose-response
relationship.
2.3.2 | In vitro mammalian cell micronucleus test
The in vitro mammalian cell micronucleus test was conducted
using the cytokinesis-block method (Fenech, 1993; Fenech &
Morley, 1985). For each experiment, cell cultures were prepared from
whole blood samples (obtained from young, 18-35-year-old, healthy,
nonsmoking donors), which were added to 8 mL of culture medium
containing phytohemagglutinin (a mitogen to stimulate the lympho-
cytes to divide; supplied by Oxoid). The cultures were incubated at
37C for 44-48 hours, before being centrifuged at 300 g for
10 minutes. Supernatants were discarded and cells were resuspended
in fresh culture medium (supplemented with S9 mix when metabolic
activation was required) and exposed to pasteurized A. muciniphila
(suspended in water for injections) for 3 hours (with 24 hours recov-
ery) in the absence or presence of S9 mix, and for 24 hours in the
absence of S9 mix (without recovery). Cytochalasin B (dissolved in
dimethyl sulfoxide) was added in to each culture to block cytokinesis.
The concentrations selected for micronucleus analysis were 187.5,
375 and 750 μg/mL for the 3-hour exposure period and 93.75, 187.5
and 375 μg/mL for the 24-hour exposure periods (the selected high
concentrations were the lowest concentrations showing precipitate in
the culture medium at the end of the exposure periods, in accordance
with OECD Test Guideline No. 487).
At harvest, the cells were collected by centrifugation (300 g for
10 minutes) and subjected to a hypotonic treatment to induce cell
swelling (i.e., incubation of 3 minutes in 4 mL of 0.075 M potassium
chloride prewarmed at 37C). The cells were then fixed in a meth-
anol/acetic acid mixture prepared by Citoxlab (both reagents were
supplied by Carlo Erba Reagents S.A.S.). Following fixation, the cells
were stored by refrigeration at 4C for at least an overnight period,
before undergoing two rounds of centrifugation (1250 g for 3 minutes)
and removal of the supernatant. The resultant cells were spread on
glass slides and stained for 7 minutes with 5% Giemsa (Merck KGaA)
in water. The slides were coded to allow for blind scoring. Micronuclei
were analyzed in 1000 binucleated cells per culture when possible
(in total, 2000 binucleated cells per concentration level in all condi-
tions). For statistical analysis, cell cultures exposed to the test item
were compared with that of the vehicle control cell cultures using the
χ2 test, in which P = .05 was used as the lowest level of significance.
To assess the dose-response trend, a linear regression was performed
between the mean frequencies of micronucleated binucleated cells
and the concentrations. This statistical analysis was performed using
SAS (version 9.2).
A positive result for clastogenicity or aneugenicity was defined as
a statistically significant increase in the frequency of micronucleated
binucleated cells in comparison with the corresponding vehicle
controls, obtained at one or more dose levels, associated with a
dose-response relationship, and for at least one concentration, the
frequency of micronucleated binucleated cells of each replicate
culture is above the corresponding vehicle historical range.
2.4 | Subchronic toxicity
2.4.1 | Animals and housing conditions
In total, 40 male and 40 female specific pathogen-free Crl:WI (Han)
rats were supplied by Charles River for the study. The animals were
5-6 weeks old at the start of the acclimatization period (lasting
12 days), with males weighing 159-191 g and females weighing
83-110 g. The study took place in an animal room supplied with
filtered air (ventilated to give 10 air changes per hour) and maintained
at a temperature of 18-24C and relative humidity of 40%-60%. A
12-hour light/dark cycle was controlled automatically. The rats were
kept in transparent polycarbonate cages (floor area: 1500 cm2 and
height: 21 cm) with two or three animals per cage, and males and
females were separated. The animals were provided with Aspen
bedding 2HV (Tapvei Estonia OÜ), as well as environmental enrich-
ment (Aspen Wood Wool; Tapvei Estonia OÜ), a wooden block (both
supplied by Tapvei Estonia OÜ) and a red transparent Rat House
(Tecniplast Gazzada S.a.r.l.). Pelleted rodent diet was available ad
libitum; Altromin 1314 Fortified diet (Altromin Spezialfutter GmbH &
Co. KG) was provided until day 49 of the dosing period, after which
the diet was switched to Altromin 1324 Fortified diet (Altromin
Spezialfutter GmbH & Co. KG) for adult animals. Domestic quality
drinking water was freely available throughout the study.
2.4.2 | Test item formulation, administration and
dosing schedule
The test item was initially divided into vials, stored under nitrogen
(to expel air and avoid oxidation) and frozen (−18C or below) until
use. On each day of dosing, the required number of vials were
defrosted and the vehicle (sterile phosphate-buffered saline previ-
ously diluted 1:9 with water) was added, before the vials were mixed
with a vortex. The resultant suspensions were administered by oral
gavage to groups of 10 males and 10 females at 75, 375 or
1500 mg/kg body weight/day (equivalent to 4.8 × 109, 2.4 × 1010 or
9.6 × 1010 A. muciniphila cells/kg body weight/day) at a dose volume
of 5 mL/kg body weight, once daily for 90 (males) or 91 (females)
days, until the day before necropsy. Animals in the vehicle control
group (also comprising 10 males and 10 females) received the vehicle
under the same conditions as animals in test item groups. The high
dose of 1500 mg/kg body weight/day (equivalent to 9.6 × 1010
A. muciniphila cells/kg body weight/day) was selected to provide a
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margin of safety of at least 100-fold compared with worst-case
exposure in foods; four- to five-fold descending intervals selected for
the mid and low doses, respectively, to demonstrate any dose-related
response in effects.
All animals were dosed within 4 hours of formulation preparation,
which was within the stability period (4 hours when stored at
room temperature protected from light and 6 hours when stored
refrigerated) confirmed as part of a separate validation study (data not
shown). A. muciniphila cell counts (conducted using flow cytometry)
were within expected ranges for test item formulations prepared for
use in weeks 1 and 13, and no A. muciniphila cells were detected in
vehicle control formulations (data not shown), which demonstrates
that formulations were accurately prepared.
2.4.3 | Clinical examinations, body weights, and food
and water consumption
All animals were observed at least once daily for changes in clinical
condition, with standard arena observations that were more compre-
hensive and conducted once weekly. Once before the first dose
administration (for all animals) and once in week 13 (for vehicle
controls and high-dose animals only) both eyes of each animal were
examined with an indirect ophthalmoscope and a portable slit-lamp
microscope after application of tropicamide 1% solution (Mydriacyl;
supplied by Alcon Universal Ltd.). On days 86 and 87 of dosing, all
animals were subjected to a modified Irwin test. The Irwin test
included a functional observation battery with assessment of sensory
reactivity to different stimuli, grip strength and motor activity. The
body weight of each animal was recorded on the first day of dosing
and weekly thereafter, until necropsy. Food and water consumption
were recorded twice weekly throughout the dosing period.
2.4.4 | Hematology, coagulation and clinical
chemistry
At the end of the dosing period (just before necropsy), blood samples
were collected from all surviving animals for hematology, coagulation
and clinical chemistry assessments. For hematology, 400 μL of blood
was collected into K3 ethylenediaminetetraacetic acid tubes (Sarstedt
AG & Co.) for analysis of the following parameters using the ABX Pen-
tra DX120SPS (Horiba): hemoglobin, red blood cell count, reticulocyte
count, hematocrit, mean cell volume, mean cell hemoglobin, mean cell
hemoglobin concentration, white blood cell count, neutrophils,
lymphocytes, eosinophils, basophils, monocytes and platelet count.
Values for coagulation parameters (activated partial thromboplastin
time, prothrombin time and fibrinogen) were determined (from 500 μL
blood samples collected into tubes; Eppendorf AG) containing 50 μL
citrate solution (129 mmol/L trisodium citrate prepared from
trisodium citrate dihydrate 294.1 g/mol; Merck KGaA) using an ACL
9000 (Instrumentation Laboratories). For clinical chemistry, 750 μL of
blood was collected into plain glass tubes for serum; values for alanine
aminotransferase, aspartate aminotransferase, alkaline phosphatase,
bilirubin, gamma-glutamyl transferase, cholesterol (total, high-density
lipoprotein and low-density lipoprotein), triglycerides, urea, creatinine,
glucose, sodium, potassium, calcium, magnesium, inorganic phospho-
rus, chloride, total protein, albumin and albumin/globulin ratio were
determined using a Cobas 6000 (Roche), values for triiodothyronine
(T3) and thyroxine (T4) by liquid chromatography with tandem mass
spectrometry and values for thyroid-stimulating hormone using xMAP
technology (Luminex; Bio-Rad Laboratories).
2.4.5 | Macroscopic examinations, organ weights
and histopathology
On the day of necropsy (days 91 and 92 for males and females, respec-
tively), all surviving animals were weighed, examined externally and (for
all females) the stage of the estrus cycle was recorded by wet vaginal
smears, before being killed by exposure to a steadily increasing concen-
tration of CO2. A macroscopic examination was performed by opening
the cranial, thoracic and abdominal cavities and observing the appear-
ance of organs and tissues in situ. For animals in all groups, specified
organs (adrenal glands, brain, epididymides, heart, kidney, liver, ovary,
pituitary gland, prostate, spleen, testes, thymus and uterus) were
weighed. A full list of organs and tissues (aorta, adrenal gland, bonemar-
row, bone from the femur, brain, caecum, colon, duodenum, epididymis,
eyes, femorotibial joint, heart, ileum, jejunum, kidney, larynx, liver,
lungs, lymph nodes [mandibular and mesenteric], mammary gland,
esophagus, optic and sciatic nerves, ovaries, pancreas, parathyroid,
pituitary, rectum, salivary glands [parotid, sublingual and submandibu-
lar], seminal vesicles, skeletal muscle, spinal cord [cervical, thoracic and
lumbar], skin, spleen, stomach, testes, thymus, thyroid, tongue, trachea,
ureter, urinary bladder, uterus and vagina) was examined microscopi-
cally for animals in the vehicle control and high-dose groups only. All
tissues were fixed in phosphate-buffered neutral 4% formaldehyde
(Hounissen), except for the eyes and testes, which were fixed in Modi-
fied Davidsons's fixative (prepared by Citoxlab from water, ethanol,
formaldehyde and acetic acid).
After fixation, the organs and tissues from vehicle control and high-
dose animals were trimmed and representative specimens were taken
for histological processing. The specimens were embedded in paraffin
wax and cut at a nominal thickness of 5 μm, before being stained with
hematoxylin and eosin and examined under a light microscope (Leica
DM3000). All pathological findings were entered directly into Instem
Provantis (version 9.3.0.0). Histological findings were graded on a five-
level scale (minimal, mild, moderate, marked and severe).
2.4.6 | Statistical analysis
Data were processed to give group mean values and standard devia-
tions where appropriate. Thereafter, each continuous variable was
tested for homogeneity of variance with Levene's test. If the variance
was homogeneous, analysis of variance was carried out for the
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variable. If any significant differences were detected, possible inter-
group differences were assessed with Dunnett's test (comparing test
item groups with a control group). If the variance was heterogeneous,
each variable was tested for normality by the Shapiro-Wilk method. In
case of normal distribution, possible intergroup differences were iden-
tified with Student's t-test. Otherwise, the possible intergroup differ-
ences were assessed by the Kruskal-Wallis test. If any significant
intergroup differences were detected, the subsequent identification
of the groups were carried out with Wilcoxon rank-sum test. Ranked
type of data were analyzed with the Kruskal-Wallis test. If any signifi-
cant intergroup differences were detected, the subsequent identifica-
tion of the groups were assessed with Wilcoxon rank-sum test. For all
tests, the level of significance was P < .05. Statistical analyses were
conducted using SAS (version 9.3) and SAS/STAT (version 12.1).
3 | RESULTS
3.1 | Genotoxicity
3.1.1 | Bacterial reverse mutation test (Ames test)
Mean revertant colony counts are provided in Table 1. An increase in
the mean number of revertants was observed at 5000 μg/plate after
short-term exposure in the absence of S9 for the TA98 strain (experi-
ment 2), and the mean value (41.3) was slightly outside the historical
control range (10-40); however, there was no evidence of a dose-
response. As this increase was not observed in the first experiment, a
third experiment was conducted using TA98 only (under the same
experimental conditions) to elucidate whether this increase was repro-
ducible. In this repeat experiment, no noteworthy increases in the
number of revertants was reported, demonstrating that the increase
in the second experiment was not reproducible and was therefore
biologically irrelevant. The overall results did not to show any biologi-
cally relevant increases in the mean number of revertant colonies fol-
lowing exposure to pasteurized A. muciniphila in any of the tested
strains compared with corresponding vehicle controls, in the presence
or absence of metabolic activation. The positive controls induced
increases in mean revertant colony numbers of at least twice (or three
times in the case of TA1535 and TA1537 strains) that of the concur-
rent vehicle controls (with metabolic activation where required),
which demonstrated the sensitivity of the assay and metabolic activity
of the S9 mix. The mean revertant colony counts for the vehicle con-
trols were within the historical control ranges of the laboratory and
there were at least five analyzable concentrations for each strain and
test condition. These results confirmed the validity of the study and
all criteria for a negative response were met.
3.1.2 | In vitro mammalian cell micronucleus test
Results for micronucleus analysis are provided in Table 2. Micro-
nucleated binucleated cell values for vehicle control groups were
within vehicle control historical ranges (data not shown) and the posi-
tive control compounds induced biologically relevant and statistically
significant increases in the frequency of micronucleated binucleated
cells under appropriate conditions, demonstrating the validity of the
assay. Following the 3- and 24-hour exposure periods, pasteurized
A. muciniphila did not induce any statistically significant or dose-
related increases in the frequency of micronucleated binucleated cells,
compared with vehicle controls. Moreover, the frequencies of micro-
nucleated binucleated cells under all conditions after exposure to the
test item were within the corresponding vehicle control historical
ranges. These results met the criteria for a negative response.
3.2 | Subchronic toxicity
3.2.1 | Clinical examinations, body weights, and food
and water consumption
There were no test item-related deaths or clinical signs (data not
shown). One female in the group given 1500 mg/kg body weight/day
was killed on day 24 of dosing due to clinical signs, including reduced
activity, periorbital tightening, slight to moderate piloerection and
markedly forced abdominal respiration. Macroscopic findings (perfo-
rated esophagus, with cloudy, thick fluid found in the thoracic cavity)
and microscopic findings (mild focal hemorrhage and neutrophilic
inflammation of the submucosa of the esophagus) were consistent
with a handling error during the dosing, rather than any effect of the
test item. There were no ocular changes and no test item-related find-
ings observed during arena observations or in the modified Irwin test.
Body weights and food consumption throughout the dosing
period are presented in Figures 1 and 2, respectively (water consump-
tion data not shown). Animals given pasteurized A. muciniphila gained
similar amounts of weight, ate similar amounts of food and drank simi-
lar amounts of water compared with vehicle controls.
3.2.2 | Hematology, coagulation and clinical
chemistry
There were no test item-related differences in values for hematology
or coagulation parameters between pasteurized A. muciniphila-dosed
groups and controls (Table 3). Statistically significant increases in
absolute neutrophil count and total white blood cell count were
observed for males given 1500 mg/kg body weight/day (9.6 × 1010
cells/kg body weight/day), but these differences were not seen for
females. All individual white blood cell count values for high-dose
males were within the historical control range (historical data not
shown), whereas three vehicle control values were below the lower
limit, indicating that the statistically significant increase for males
given 1500 mg/kg body weight/day was likely attributable to control
values being lower than expected for animals of this age and strain,
rather than any effect of the test item. Furthermore, all but one of the
individual absolute neutrophil values for high-dose males were within



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 DRUART ET AL.
the historical control range (one value [2.71 × 109/L] being only nar-
rowly above the upper limit [2.70 × 109/L]), showing that these values
also reflected normal biological variation. Statistically significant
reductions in relative eosinophils for low- and mid-dose males were
clearly unrelated to the test item, as the differences were not
observed in the high-dose group.
No biologically relevant or statistically significant differences in
coagulation or blood chemistry parameters were observed between
controls and test item groups (Table 4). Statistically significant
increases in T3 and T4 for low-dose males, and in T4 for males given
1500 mg/kg body weight/day, were considered unrelated to the test
item as they were not associated with a dose response.
3.2.3 | Macroscopic examinations, organ weights
and histopathology
Organ weights relative to body weight are provided in Table 5. There
were no differences in organ weights between controls and pasteur-
ized A. muciniphila-dosed groups. There were also no test item-related
macroscopic or microscopic findings (data not shown). The only find-
ings observed were incidental and generally consistent with changes
encountered in rats of this age and strain kept under laboratory condi-
tions (data not shown).
4 | DISCUSSION
The majority of probiotics sold on the market mainly include microor-
ganisms from the genera Lactobacillus and Bifidobacterium (Douillard &
de Vos, 2014). However, much data support the interest of next gen-
eration beneficial bacteria in providing health benefit to humans
(O'Toole, Marchesi, & Hill, 2017). The safety of these novel microbes
for human consumption has to be evaluated carefully (Brodmann
et al., 2017).
A. muciniphila is one of the most abundant single species in the
human intestinal microbiota (0.5%-5% of the total bacteria) but was
only isolated and characterized in 2004 (Collado et al., 2007; Derrien
et al., 2004). The bacterium is present in the human gut from infancy
and cells have been detected in breast milk and its abundance
increases significantly during growth into adulthood (Geerlings
et al., 2018). Over the last 10 years, numerous studies have found that
the bacterium A. muciniphila was positively associated with healthy
gut lining, reduced metabolic disorders and decreased low-grade
inflammation (Cani & de Vos, 2017). In addition, the abundance of the
bacterium is strongly increased upon gastric bypass or antidiabetic
drug treatment such as metformin (Forslund et al., 2015; Liou
et al., 2013). The administration of live A. muciniphila has been associ-
ated with several beneficial effects on cardiometabolic risk factors
(Everard et al., 2013; Shin et al., 2013). It was only in 2017 that the
strong metabolic effects of pasteurized A. muciniphila were described
(Plovier et al., 2005) and then confirmed in other studies (Depommier
et al., 2020; Wang et al., 2019). The beneficial effects of consuming
microorganisms inactivated by pasteurization for 30 minutes at 70C,
a mild heat treatment limiting the denaturation of cellular compo-
nents, have also been described in previous studies (Peng &
Hsu, 2015; Sakai et al., 2017). Therefore, pasteurization of
A. muciniphila, provides enhanced beneficial health effects (compared
with live A. muciniphila) as well as increased stability and negligible risk
of toxicity.
As A. muciniphila is part of nutrition in the early stages of life
(Collado et al., 2012) and is a commensal gut bacterium constituting
3%-5% of the gut microbiota, it would reasonably be expected to
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–S9, without metabolic activation; +S9, with metabolic activation; COL,
colchicine; CPA, cyclophosphamide; MMC, mitomycin C; RI, replication
index.
**Statistically significantly different from vehicle control (P < .01).
***Statistically significantly different from vehicle control (P < .001).
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be safe for human consumption. Furthermore, the development of
pasteurized A. muciniphila still reinforces this safety aspect, as the
pasteurized bacterium is unable to replicate or to colonize the human
gut. Other heat-killed bacteria, even some bacteria close to pathogens
from a taxonomic point of view, have already been recognized as safe
by EFSA (2015, 2019). There are also previously published studies
assessing the safety of A. muciniphila (Brodmann et al., 2017;
Cozzolino et al., 2020; Gómez-Gallego et al., 2016; Zhang, Li, Cheng,
Buch, & Zhang, 2020); however, to the best of our knowledge, this is
the first article reporting the findings of studies conducted with
A. muciniphila according to the requirements of the US FDA and EFSA
guidances on toxicity testing required for the safety assessment of a
novel nonabsorbable food ingredient (EFSA, 2012; US FDA
Redbook, 2014).
Pasteurized A. muciniphila has been demonstrated to have only
beneficial effects for humans and administration of pasteurized
A. muciniphila was not associated with any notable change to the
overall pattern of gut microbiota and abundance of other bacterial
species in humans and rodents (Depommier et al., 2019; Everard
et al., 2013; Li, Lin, Vanhoutte, Woo, & Xu, 2016). A randomized,
double-blind, placebo-controlled proof-of-concept study in over-
weight/obese insulin-resistant volunteers showed that the daily
supplementation with pasteurized A. muciniphila at a dose of 1 × 1010
cells/day for 12 weeks was well tolerated and improved several
metabolic parameters (i.e., insulin sensitivity, insulinemia, plasma total
cholesterol as well as relevant blood markers for liver dysfunction and
inflammation) (Depommier et al., 2019). In addition, as pasteurized
A. muciniphila has been heat-treated, it will not colonize the intestine
and is primarily excreted as dead bacteria in feces, as demonstrated
previously using rRNA gene-based detection methods (Depommier
et al., 2019).
Despite there being no reported adverse effects associated with
A. muciniphila in previously conducted studies, in addition to the high
prevalence of A. muciniphila in the gastrointestinal tract of virtually all
healthy humans and its presence in breast milk, there are no data
available or any documented history of use as a food ingredient. Thus,
given the vastly increasing amount of scientific research showing an
interest to propose pasteurized A. muciniphila as a potential food
ingredient, an appropriate toxicological evaluation was warranted.
The methodology for the safety assessment of pasteurized
A. muciniphila follows the tiered approach to toxicity testing proposed
by EFSA and the US FDA Redbook guidance on safety assessment of
food ingredients (EFSA, 2012; US FDA Redbook, 2014). This approach
involves assessment of potential genotoxicity using the bacterial
reverse mutation and in vitro mammalian cell micronucleus tests,
followed by a 90-day oral toxicity study to assess the potential for
subchronic toxicity.
The results of the in vitro genotoxicity tests demonstrated that
pasteurized A. muciniphila is neither mutagenic (as assessed in the bac-
terial reverse mutation test) nor clastogenic or aneugenic (as assessed
in the in vitro mammalian cell micronucleus test). In the 90-day study,
there were no test item-related adverse effects on clinical observa-
tions, neurobehavioral assessments, body weight, food consumption,
water consumption, clinical pathology, organ weights or histopathol-
ogy. Statistically significant differences in leukocyte counts for
pasteurized A. muciniphila-administered groups compared with vehicle
F IGURE 1 Body weights of
rats during the 90-day study. A,
Male. B, Female. bw, body weight
F IGURE 2 Food
consumption of rats during the
90-day study. A, Male. B, Female.
bw, body weight
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controls were minimal, limited to one gender and individual values
were generally within historical control ranges, thus reflecting normal
biological variation. Absence of any associated changes in organ
weights, or of any corresponding macroscopic or histopathological
findings, confirms that these differences were likely to be incidental,
rather than a direct result of pasteurized A. muciniphila administration.
Therefore, the no-observed-adverse-effect level (NOAEL) for the
90-day study was concluded to be 1500 mg/kg body weight/day
(9.6 × 1010 cells/kg body weight/day), the highest dose tested. This
NOAEL provides a safety factor of over 100-fold when compared
with the worst-case anticipated exposure from use in foods; 100-fold
is considered the minimum required safety factor when applying ani-
mal experimentation data to humans (21 CFR 170.22; US FDA, 2000).
In conclusion, the negative in vitro genotoxicity results, combined
with the absence of any test item-related adverse effects in the
90-day toxicity study, support the safety of pasteurized A. muciniphila
for use as a food ingredient.
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